SEARCH

SEARCH BY CITATION

References

  • 1
    Food and Drug Administration. FDA approves VariZIG for reducing chickenpox symptoms. Silver Spring, MD: Food and Drug Administration; 2012. Available at http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm333233.htm.
  • 2
    Cangene Corporation. VariZIG: varicella zoster immune globulin (human). [package insert]. Winnipeg, Canada: Cangene Corporation; 2013.
  • 3
    American Academy of Pediatrics. Varicella-zoster infections. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red book: 2012 report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics 2012, 77489.
  • 4
    Brunell PA, Ross A, Miller LH, Kuo B. Prevention of varicella by zoster immune globulin. N Engl J Med 1969; 280: 11914.
  • 5
    Brunell PA, Gershon AA, Hughes WT, Riley HD Jr, Smith J. Prevention of varicella in high risk children: a collaborative study. Pediatrics 1972; 50: 71822.
  • 6
    Gershon AA, Steinberg S, Brunell PA. Zoster immune globulin. A further assessment. N Engl J Med 1974; 290: 2435.
  • 7
    Zaia J, Levin MJ, Preblud SK, et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983; 147: 73743.
  • 8
    Levin MJ, Nelson WL, Preblud SR, Zaia JA. Clinical trials with varicella-zoster imunoglobulins. In: Movell A, Nydegger U, eds. Clinical use of intravenous imunoglobulins. London, UK: Academic Press Inc.; 1986, 25567.
  • 9
    CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007; 56: (No. RR-4).
  • 10
    CDC. A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR 2006; 55: 20910.
  • 11
    CDC. FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. MMWR 2012; 61: 212.
  • 12
    Evans EB, Pollock TM, Cradock-Watson JE, Ridehalgh MK. Human anti-chickenpox immunoglobulin in the prevention of chickenpox. Lancet 1980; 1: 3546.
  • 13
    Miller E, Marshall R, Vurdien J. Epidemiology, outcome and control of varicella-zoster infection. Reviews in Medical Microbiology 1993; 4: 22230.
  • 14
    Enders G, Miller E. Varicella and herpes zoster in pregnancy and the newborn. In: Arvin A, Gershon A, eds. Varicella-zoster virus: virology and clinical management. Cambridge, UK: Cambridge University Press 2000.
  • 15
    Koren G, Money D, Boucher M, et al. Serum concentrations, efficacy, and safety of a new, intravenously administered varicella zoster immune globulin in pregnant women. J Clin Pharmacol 2002; 42: 26774.
  • 16
    Winsnes R. Efficacy of zoster immunoglobulin in prophylaxis of varicella in high-risk patients. Acta Paediatr Scanda 1978; 67: 7782.